Advertisement Lannett gets FDA approval for anti-obesity treatment - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Lannett gets FDA approval for anti-obesity treatment

Lannett has received the US Food and Drug Administration (FDA) approval for the abbreviated new drug application (ANDA) of Phentermine Resin Extended-Release Capsules, 15mg and 30mg.

Lannett’s Phentermine Resin Extended-Release Capsules, 15mg and 30mg is the generic version of UCB’s Ionamin Capsules, 15mg and 30mg.

Phentermine Resin is indicated in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction.

Cody Laboratories, the pain management subsidiary of Lannett, is responsible for producing the active pharmaceutical ingredient (API) of the product.